New York Eye and Ear Infirmary
Adjust: Text Size Make Font Smaller Make Font Larger Print this Page: Normal Print Friendly Large Print Friendly Accessibility Info

A 3-Year, Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial to Assess the Safety and Efficacy of 700 µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS Applicator System) in the Treatment of Patients with Diabetic Macular Edema

Principal Investigator

Richard Rosen, MD

Enrollment Status

Completed

Objective

To evaluate the safety and efficacy of the 700 µg DEX PS DDS Applicator System (700 µg dexamethasone) and 350 µg DEX PS DDS Applicator System (350 µg dexamethasone) in patients with diabetic macular edema.

Eligibility:

Contact Principal Investigator/Coordinator

Contact Information:

  • Principal Investigator: Richard Rosen, MD at (212) 979-4284
  • Study Coordinator: Julie Paa, CRC (212) 979-4024
  • Katy Tai, CR Manager (212) 979-4251

 

Home > Current Research > Clinical Trials in Ophthalmology > A 3-Year, Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial to Assess the Safety and Efficacy of 700 µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS Applicator System) in the Treatment of Patients with Diabetic Macular Edema